Biogen Idec turns 30

CAMBRIDGE, Mass. This week marks the 30th anniversary of the biotech Biogen Idec.

“For 30 years, Biogen Idec has been transforming discoveries into breakthrough therapies that improve the lives of patients around the world,” said James Mullen, Biogen Idec’s chief executive officer. “With leading biotechnology products, a robust pipeline and talented people, we are delivering significant value for our patients and shareholders. Our prospects for future growth and success have never been better.”

Currently, Biogen Idec markets three major therapies. It has a multiple sclerosis franchise with Avonex and Tysarbi, which is co-marketed with Elan Pharmaceuticals. The company also co-markets with Genentech, Rituxan, a treatment for non-Hodgkin’s lymphoma and rheumatoid arthritis.

The company’s product pipeline includes 15 products in Phase 2 and beyond, and its research and development is focused primarily on neurology, oncology and rheumatology, with emerging efforts in cardiopulmonary diseases and hemophilia.

Phillip Sharp, co-founder and a director of the company, said, “Thirty years ago, we could only have dreamed that the company we started would have the profound impact on patients that it has today. It is gratifying to see Biogen Idec’s spirit of innovation and perseverance continuing to drive excellence in research and development. The company has also outlined a comprehensive strategic growth plan that we believe will build on the exciting momentum underway.”